CD38 and Miyoshi myopathy: In the setting of rare MM presentations, such as lung plasmacytoma, with unfavorable clinical outcomes, we showed that anti‐CD38 monoclonal antibodies in combination with targeted therapies could be an effective treatment option in patients with newly diagnosed MM with pulmonary EMD.